外周血B7-H2联合白细胞介素-6水平变化在胆管癌诊断及预后评估中的价值

The value of peripheral blood B7-H2 combined with interleukin 6 level in the diagnosis and prognosis of cholangiocarcinoma

目的探究外周血B7-H2联合白细胞介素6(IL-6)水平变化在胆管癌诊断及预后评估中的价值。方法收集自2015年1月1日-2018年1月1日收入本院肝胆外科的老年胆管癌患者99例,利用ELISA试剂盒检测血清中B7-H2联合IL-6水平变化,利用Pearson相关性分析血清中协同刺激分子B7-H2与IL-6水平的相关性,并且利用生存曲线分析胆管癌根治术后的预后情况。结果 99例老年胆管癌患者均获得随访,随访率为100%,TNM分期、淋巴转移和远处转移患者中B7-H2和IL-6的高水平与低水平表达差异有统计学意义(P<0.05)。实验组胆管癌患者外周血淋巴细胞表面B7-H2的表达高于对照组患者B7-H2的表达量(P<0.05)。胆管癌术后患者的预后生存率与血清中B7-H2和IL-6表达的生存曲线结果显示,血清中B7-H2和IL-6的表达与胆管癌的预后差异有统计学意义(P<0.05)。结论 B7-H2和IL-6的表达水平与胆管癌的发生和进展具有相关性,可以作为胆管癌筛查检测预后的分子标记物。

Objective To investigate the value of B7-H2 combined with interleukin-6 in the diagnosis and prognosis of cholangiocarcinoma. Methods Ninety-nine elderly patients with cholangiocarcinoma admitted to our department of hepatobiliary surgery from January 1, 2015 to January 1, 2018 were collected. The serum levels of B7-H2 and interleukin-6 were detected by ELISA kit. The correlation between B7-H2 and interleukin-6 was analyzed by Pearson correlation analysis. Survival curve was used to analyze the prognosis after radical resection of cholangiocarcinoma. Results A total of 99 elderly patients with cholangiocarcinoma were followed up. The follow-up rate was 100%. There was statistical significance on the differences between the high and the low levels of B7-H2 and IL-6 in lymphatic metastasis and distant metastasis(P<0.05). The expression of B7-H2 on peripheral blood lymphocyte surface in experimental group was significantly higher than that in control group(P<0.05). The prognostic survival rate and the survival curve of B7-H2 and IL-6 in serum of patients with colorectal cancer after operation showed that the levels of B7-H2 and IL-6 in serum was significantly different from the prognosis of cholangiocarcinoma, and the differences were statistically significant(P<0.05). Conclusion The levels of B7-H2 and IL-6 are correlated with the occurrence and progression of cholangiocarcinoma and can be used as molecular markers for the screening and prognosis of cholangiocarcinoma.